Background: Mild cognitive impairment (MCI) represents an intermediate state between normal cognition and dementia. Early detection and treatment of reversible contributing factors to progressive cognitive decline currently forms the cornerstone of management. As the population at risk of developing dementia is projected to increase significantly in many low- and middle-income countries where health care services continue to operate under clinical and human resource constraints, there is a need for low-cost, quick and reliable screening tools. The Montreal cognitive assessment (MoCA) was developed as a brief screening tool with high sensitivity and specificity for detecting MCI. The initial validation sample for the MoCA consisted of Englis...
Contains fulltext : 87418.pdf (publisher's version ) (Closed access)OBJECTIVE: The...
BACKGROUND: The Montreal Cognitive Assessment (MoCA) was developed to enable earlier detection of mi...
BACKGROUND: HIV-associated neurocognitive disorders (HAND) are frequently occurring comorbidities in...
The validity of the Montreal Cognitive Assessment (MoCA) as a screen for mild cognitive impairment (...
The aim of this study was to determine the clinical utility of the Finnish version of the MoCA test ...
Introduction: There is an urgent need to validate telephone versions of widely used general cognitiv...
OBJECTIVE: The aim of this study was to report on the prevalence of cognitive impairment, and to as...
Update on the Montreal Cognitive Assessment (MoCA) (J.F.M. de Jonghe): This presentation aims to pro...
$\textbf{Background:}$ Dementia is a progressive syndrome of global cognitive impairment with signi...
Background: The Montreal Cognitive Assessment (MoCA) is a brief cognitive schedule that has been dev...
Montreal Cognitive Assessment (MoCA) is a new cognitive tool developed for screening mild cognitive ...
Background: HIV-associated neurocognitive disorders (HAND) are frequently occurring comorbidities in...
The Montreal Cognitive Assessment (MoCA) is a brief instrument developed for the screening of milder...
The Montreal Cognitive Assessment (MoCA) is a rapid screening battery, also including subtests to as...
The Montreal Cognitive Assessment (MoCA) is a brief instrument developed for the screening of milder...
Contains fulltext : 87418.pdf (publisher's version ) (Closed access)OBJECTIVE: The...
BACKGROUND: The Montreal Cognitive Assessment (MoCA) was developed to enable earlier detection of mi...
BACKGROUND: HIV-associated neurocognitive disorders (HAND) are frequently occurring comorbidities in...
The validity of the Montreal Cognitive Assessment (MoCA) as a screen for mild cognitive impairment (...
The aim of this study was to determine the clinical utility of the Finnish version of the MoCA test ...
Introduction: There is an urgent need to validate telephone versions of widely used general cognitiv...
OBJECTIVE: The aim of this study was to report on the prevalence of cognitive impairment, and to as...
Update on the Montreal Cognitive Assessment (MoCA) (J.F.M. de Jonghe): This presentation aims to pro...
$\textbf{Background:}$ Dementia is a progressive syndrome of global cognitive impairment with signi...
Background: The Montreal Cognitive Assessment (MoCA) is a brief cognitive schedule that has been dev...
Montreal Cognitive Assessment (MoCA) is a new cognitive tool developed for screening mild cognitive ...
Background: HIV-associated neurocognitive disorders (HAND) are frequently occurring comorbidities in...
The Montreal Cognitive Assessment (MoCA) is a brief instrument developed for the screening of milder...
The Montreal Cognitive Assessment (MoCA) is a rapid screening battery, also including subtests to as...
The Montreal Cognitive Assessment (MoCA) is a brief instrument developed for the screening of milder...
Contains fulltext : 87418.pdf (publisher's version ) (Closed access)OBJECTIVE: The...
BACKGROUND: The Montreal Cognitive Assessment (MoCA) was developed to enable earlier detection of mi...
BACKGROUND: HIV-associated neurocognitive disorders (HAND) are frequently occurring comorbidities in...